Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Tomoya Yokota"'
Autor:
Yoshiyuki Iida, Takanori Kawabata, Tomoya Yokota, Hirofumi Ogawa, Takashi Mukaigawa, Yusuke Onozawa, Tsuyoshi Onoe, Satoshi Hamauchi, Hirofumi Yasui, Ari Nishimura, Hiromichi Shirasu
Publikováno v:
International Journal of Clinical Oncology. 26:1822-1830
Distant metastasis is a poor prognostic factor in recurrent/metastatic squamous cell carcinoma of the head and neck. However, limited information on the prognostic impact of locoregional disease is available, despite its life-threatening features. We
Autor:
Ari Nishimura, Tomoya Yokota, Satoshi Hamauchi, Yusuke Onozawa, Akifumi Notsu, Fuyuki Sato, Takeshi Kawakami, Hirofumi Ogawa, Tsuyoshi Onoe, Takashi Mukaigawa
Publikováno v:
BMC cancer. 22(1)
Background Postoperative chemoradiotherapy (CRT) is a standard therapy for patients with high-risk factors for head and neck squamous cell carcinoma, including positive margin and extra-nodal extension (ENE). However, the prognostic impact of the num
Autor:
Tetsuo Akimoto, Tomoya Yokota, Hirofumi Fujii, Yosuke Ota, Torahiko Nakashima, Nobuya Monden, Takeshi Kodaira, Shinya Ueda, Mototsugu Shimokawa, Akihiro Homma
Publikováno v:
International Journal of Clinical Oncology. 26:316-325
The aims of this study are to evaluate the efficacy and safety of first-line treatment with chemotherapy plus cetuximab in real-world patients with recurrent or metastatic squamous cell carcinoma of the head and neck (RM-SCCHN) and to identify progno
Autor:
Ken Kato, Shuichi Hironaka, Takashi Kojima, Hiroki Hara, Hisayuki Matsushita, Yuko Kitagawa, Yoshinori Ito, Takayuki Kii, Yasuo Hamamoto, Keisho Chin, Yasuhiro Tsubosa, Rie Nagumo, Hirofumi Ogawa, Yasushi Kojima, Kentaro Kawakami, Takashi Makiuchi, Yasunori Akutsu, Tomoya Yokota, Keita Mori, Takashi Ura
Publikováno v:
Annals of Surgical Oncology. 27:460-467
A multicenter phase 2 trial analysed chemoselection with docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy (ICT) and subsequent conversion surgery (CS) for locally advanced unresectable esophageal cancer. This study presents up
Autor:
Yukio Yoshida, Tomoya Yokota, Takahiro Tsushima, Akira Fukutomi, Yusuke Onozawa, Satoshi Hamauchi, Kentaro Yamazaki, Hirofumi Yasui, Masahiro Kawahira, Sadayuki Kawai, Nozomu Machida, Akiko Todaka
Publikováno v:
International Journal of Clinical Oncology. 23:1189-1195
The efficacy of primary prophylactic granulocyte colony-stimulating factor (G-CSF) in preventing febrile neutropenia (FN) in patients treated with docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy remains controversial. We compared the inci
Autor:
Nozomu Machida, Akiko Todaka, Akira Fukutomi, Takeshi Kawakami, Katsuhiro Omae, Satoshi Hamauchi, Hiromichi Shirasu, Yukio Yoshida, Tomoya Yokota, Takahiro Tsushima, Kentaro Yamazaki, Yusuke Onozawa, Yosuke Kito, Hirofumi Ogawa, Hirofumi Yasui
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
BMC Cancer
BMC Cancer
Background Standard treatment for unresectable esophageal squamous cell carcinoma (ESCC) without distant metastasis is definitive chemoradiotherapy (dCRT), in which the incidence of esophageal fistula (EF) is reported to be 10–12%. An ad hoc analys
Autor:
Hiroshi Sato, Shuhei Mayanagi, Yasuhiro Tsubosa, Takahiro Tsushima, Tomoya Yokota, Tsuneyuki Uchida, Masahiro Niihara, Tateaki Naito, Katsuhiro Omae, Hirofumi Yasui
Publikováno v:
Annals of Surgical Oncology
Background Skeletal muscle wasting during curative treatment is an important issue faced by esophageal cancer patients. However, it has not been clarified whether skeletal muscle change during neoadjuvant chemotherapy followed by surgery adversely af
Autor:
Yukiya Narita, Masahiro Tajika, Akiko Todaka, Toshiki Masuishi, Tomoya Yokota, Yusuke Onozawa, Kei Muro, Hirofumi Yasui, Kentaro Yamazaki, Tsutomu Tanaka, Hiroya Taniguchi, Azusa Komori, Yosuke Kito, Satoshi Hamauchi, Keita Mori, Makoto Ishihara, Takashi Ura, Masashi Ando, Nozomu Machida, Akira Fukutomi, Shigenori Kadowaki, Takahiro Tsushima
Publikováno v:
Clinical Colorectal Cancer. 16:51-57
Background TAS-102 significantly improves overall survival in patients with metastatic colorectal cancer. The most common treatment-related adverse event of TAS-102 is bone marrow suppression, which leads to neutropenia. The potential predictive valu
Autor:
Akira Fukutomi, Yosuke Kito, Nozomu Machida, Hirofumi Yasui, Tomoya Yokota, Yusuke Onozawa, Akiko Todaka, Satoshi Hamauchi, Toshiki Masuishi, Yukiya Narita, Kei Muro, Kentaro Yamazaki, Keita Mori, Azusa Komori, Tsutomu Tanaka, Makoto Ishihara, Takashi Ura, Takahiro Tsushima, Masahiro Tajika, Hiroya Taniguchi, Masashi Ando, Shigenori Kadowaki
Publikováno v:
Oncology. 93:329-335
Purpose: Regorafenib improves survival in chemorefractory metastatic colorectal cancer (mCRC) patients. However, regorafenib induces various adverse events (AEs) that often impair patients' quality of life. Identification of early predictive markers
Autor:
Akihiro Homma, S. Zenda, Takeshi Kodaira, Takenori Ogawa, Hirofumi Fujii, Shigemichi Iwae, Nobuhiro Hanai, Koichiro Yonezawa, Tetsuro Onitsuka, Susumu Okano, Tomoya Yokota, Shunji Takahashi, Kazuto Matsuura, Yasushi Shimizu, Makoto Tahara, Tetsuo Akimoto, Naomi Kiyota, Ryuichi Hayashi, Takahiro Asakage, Nobuya Monden
Publikováno v:
Japanese journal of clinical oncology. 49(7)
A number of major modifications were made to the classification of head and neck carcinomas in the eighth edition of the American Joint Committee on Cancer, Cancer Staging Manual and Union for International Cancer Control TNM classification of Malign